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PCIPhotochemical internalisation (PCI) is a site-speciﬁc technique for improving cellular delivery of macromo-
lecular drugs. In this study, a cell penetrating peptide, containing the core HIV-1 Tat 48–57 sequence, conju-
gated with a porphyrin photosensitiser has been shown to be effective for PCI. Herein we report an
investigation of the photophysical and photobiological properties of a water soluble bioconjugate of the cat-
ionic Tat peptide with a hydrophobic tetraphenylporphyrin derivative. The cellular uptake and localisation of
the amphiphilic bioconjugate was examined in the HN5 human head and neck squamous cell carcinoma cell
line. Efﬁcient cellular uptake and localisation in endo/lysosomal vesicles was found using ﬂuorescence detec-
tion, and light-induced, rupture of the vesicles resulting in a more diffuse intracellular ﬂuorescence distribu-
tion was observed. Conjugation of the Tat sequence with a hydrophobic porphyrin thus enables cellular
delivery of an amphiphilic photosensitiser which can then localise in endo/lysosomal membranes, as re-
quired for effective PCI treatment. PCI efﬁcacy was tested in combination with a protein toxin, saporin, and
a signiﬁcant reduction in cell viability was measured versus saporin or photosensitiser treatment alone.
This study demonstrates that the cell penetrating peptide-photosensitiser bioconjugation strategy is a prom-
ising and versatile approach for enhancing the therapeutic potential of bioactive agents through photochem-
ical internalisation.F, dimethylformamide; DMPC,
rnalisation; PDT, photodynamic
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Photochemical Internalisation (PCI) is a technology developed by Berg
and co-workers [1–3], which can enhance drug delivery using light in
combination with photosensitisers localised in endo/lysosomal mem-
branes. The technique is aimed at improving the delivery of bioactive
agents which become sequestered within endo/lysosomal vesicles and
are therefore unable to exert their action upon the target site. With
PCI, the light-induced rupture of the photosensitised vesicle membranes
enables the agents to reach their intracellular target. The aim of this
study was to investigate whether a cell penetrating peptide bioconjugate
can be used to enhance drug delivery.
Pharmaceutical agents can suffer from low bioavailability due either
to poor cell membrane penetration and/or the lack of water solubility.
In tackling this key problem in drug delivery, an active area of researchto improving bioavailability is the conjugation of drugs with cell pene-
trating peptides (CPP), which can enhance the water solubility and cel-
lular uptake of drugs [4]. Two studies independently reported the cell
membrane translocation ability of the trans-activating transcriptional
activator (Tat), a protein from human immunodeﬁciency virus type I
(HIV-1) [5,6] using the 86-mer Tat or the puriﬁed Tat protein. Both
Tat proteins were able to enter cultured cells and induce the trans-
activation of the viral promoter. The full-length protein was soon char-
acterised as a protein with multiple functional domains [7,8] and the
highly basic region which contains six arginine and two lysine in nine
residues is assigned to the protein translocation activity [9]. Since
then, other natural or designed proteins or peptides have also demon-
strated the property of translocation [10]. These proteins and peptides
all contain the highly positive charged protein transduction domains
(PTDs) or cell penetrating peptides (CPPs) that are responsible for pro-
tein transduction, i.e. the translocation process across the cell
membrane.
Several approaches to linking pharmaceutical cargos to Tat pep-
tides or other CPPs to overcome the cell membrane barrier have
been carried out. To date, Tat peptides have been proven to facilitate
the cell entry of various molecules ranging from peptides [11] with
molecular weights of hundreds of Dalton to larger structures such
as liposomes [12]. The remarkable success of Tat peptides in drug de-
livery has drawn considerable attention to the mechanisms involved
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uptake was found when Tat peptides were modiﬁed with a single de-
letion or substitution of the core sequence ‘GRKKRRQRRR’ in the basic
domain resulting in a change of charges [13,14]. Diminished cellular
uptake indicated the unique highly cationic nature of Tat peptides
certainly plays a key role in the cell uptake process, and the direct
electrostatic interaction between the positively charged Tat peptides
and the negatively charged proteoglycans or glycosaminoglycans
on the cell surface is believed to be required in the internalisation
mechanism [15,16].
Despite earlier misinterpretations of the uptake mechanism
resulting from artefacts caused during the cell ﬁxation procedures,
endocytic uptake is the generally recognised mechanism for Tat pep-
tide and most other CPP mediated drug delivery [17,18]. Both lipid
raft-mediated caveolar endocytosis and the clathrin-mediated endo-
cytosis have been identiﬁed as endocytic routes of Tat-fusion proteins
[19,20], in addition to macropinocytosis, a rapid non-speciﬁc lipid raft
cell uptake pathway [21]. To date, more than 20 Tat-derived short
peptides with various modiﬁcations at either the N-terminal or the
C-terminal ends have been used for delivering drugs into cells [22].
The advantages and versatility of the Tat peptide-mediated drug de-
livery have also been applied in vivo. For example, a study conducted
by Schwarze et al. used a Tat fusion protein (120 kD) in which β-
galactosidase (116 kD) was ligated to the protein transduction domain
[23]. After intraperitoneal injection in mice, the conjugate was found to
distribute into virtually every organ and even cross the blood brain bar-
rier after 4 h. These promising results have led to the possibility of Tat
peptides being used for in vivo drug delivery.
Porphyrins and their analogues constitute the major class of
photosensitising agents in photodynamic therapy (PDT), which is a
local treatment for both malignant and no-malignant pathologies.
Its therapeutic effects arise from the photo-oxidative damage initiat-
ed by the photosensitised generation of reactive oxygen species [24].
As with other pharmaceutical agents, many photosensitising agents
exhibit poor bioavailability being either too hydrophilic or conversely
too hydrophobic and with limited water solubility. Conjugation strat-
egies that modify photosensitisers by linking to certain peptides or
proteins with targeting function have been used to improve the selec-
tivity of photosensitiser delivery [25,26]. For example, penetratin
coupled to 5-aminolevulinic acid was shown to be taken up by cells
and could be successfully converted to photoporphyrin IX via the
haem biosynthetic pathway [27]. CPP-porphyrin conjugates have
been recently synthesised as photoactive compounds. Sibrian-
Vazquenz et al. synthesised different porphyrin-peptide conjugates
bearing PEG linkers to several targeting sequences including the Tat
peptide (48–60) to compare their cellular uptake, subcellular localisa-
tion and the phototoxicity in vitro [28]. Sehgal et al., from the same
group, examined the cellular uptake and phototoxicity of ﬁve
porphyrin-peptide conjugates using a prostate cancer cell line [29].
Recently we have also shown that a Tat-porphyrin conjugate is effec-
tive for antimicrobial PDT [30].
In photochemical internalisation (PCI), the light-induced rupture of
the endo/lysosomal membranes enables therapeutic agents seques-
tered within endo/lysosomes to reach their intracellular target. In con-
trast to photodynamic therapy, PCI is a site-speciﬁc drug delivery
technique where the therapeutic action is exerted by the drug itself
but not the by photosensitiser or the reactive oxygen species. For exam-
ple, previous studies in our laboratory have demonstrated successful re-
versal of doxorubicin drug resistance in vitro by PCI [31,32]. Other
agents successfully delivered using PCI include siRNA [2] and a peptide
nucleic acid (PNA), where the PNAwas conjugated to a cell penetrating
peptide but not the photosensitiser [33].
Using an in vivo rat livermodel, we have also demonstrated that PCI-
mediated release of low doses of a protein toxin can give enhanced tis-
sue damage [1]. Type I ribosome inactivating proteins (RIPs) such as
gelonin and saporin exert a lethal effect on protein synthesis only ifdelivered into the cytosol, however due to their size they can become
sequestered within endo/lysosomes [34]. Enhanced drug delivery of
saporin and other RIPs (gelonin) to the cytosol has previously been
demonstrated using PCI technology and amphiphilic disulfonated
photosensitisers in vitro [35–37]. These amphiphilic disulfonated photo-
sensitisers were selected since they exhibit preferential localisation in
endo/lysosomal membranes in order to promote the PCI effect. It is im-
portant to note that the criteria for selection of a photosensitiser for PCI
are distinct from PDTwhere localisation in several subcellular compart-
ments may confer an advantage (e.g. in mitochondria) rather than the
speciﬁc endo/lysosomal localisation required for PCI. Identiﬁcation and
optimisation of new photosensitising compounds for PCI therefore pre-
sents a different experimental challenge.
In the present study, we investigated the hypothesis that a Tat-TPP
conjugate could be particularly suitable for PCI because of the resulting
amphiphilicity conferred by cationic Tat peptide sequence and the hy-
drophobic porphyrin. Such an amphiphilic structure should favourmem-
brane binding essential for PCI, but retain good water solubility. The
presence of the CPP moiety should in principle favour endo/lysosomal
uptake but, unlike CPP-mediated drug delivery where segregation with-
in these vesicles is a drawback, with PCI the CPP-photosensitiser conju-
gate is used to induce rupture of these vesicles for co-delivery of the
bioactive agent. Photophysical and biological studies of a peptide-
porphyrin conjugate were carried out to assess its efﬁcacy for PCI in en-
hancing intracellular delivery and cytotoxicity of the macromolecular
toxin, saporin.2. Materials and methods
2.1. Chemicals
Chemical reagentswere purchased fromSigma-Aldrich (Gillingham,
UK), Fluka (Gillingham, UK), Acros (Loughborough, UK), Lancaster
(Lancashire, UK) and Novabiochem (Nottingham, UK). All other sol-
vents were purchased from Fisher Scientiﬁc (Loughborough, UK) and
used as received. Peptide grade dimethylformamide was purchased
from Rathburn Chemicals Ltd. (Walkerburn, UK). Preparative RP-HPLC
was performed on a Dionex HPLC system (Leeds, UK) consisting of an
Ultimate 3000 WPS autosampler, a P680 preparative pump (HPG), a
UVD 170U multiwavelength detector, and a Foxy Jr fraction collector.
The puriﬁcations were performed on a Phenomenex Gemini 5 μm C-
18 (250×30 mm) column with a ﬂow rate of 22.5 ml/min. Mobile
phase Awas 0.1% TFA in water, mobile phase Bwas 0.1% TFA in acetoni-
trile. High resolution mass spectrometry was performed using a Bruker
MicroTOF autospec ESImass spectrometer (Coventry, UK). TPPS4 (tetra-
sulfonated tetraphenylporphine) was supplied by Frontier Scientiﬁc
(Frontier Scientiﬁc Europe, Lancashire, UK). TPPS2a (disulfonated tetra-
phenylporphine) was a gift from PCI Biotech (Oslo, Norway).2.2. Synthesis of Tat-TPP conjugate
The Tat-TPP conjugate 2 was prepared by the ligation of the mal-
eoylporphyrin derivative 1 (5 eq) to a HIV-1 Tat 48–57 analogue
(1 eq), wherein the peptide was extended at the C-terminus by the
tetrapeptide amide GYKC-NH2 (Fig. 1), as used elsewhere [38]. The
peptide was synthesised by 9-ﬂuorenylmethoxycarbonyl (Fmoc)-
SPPS, and the ligation reaction was performed in solution in DMSO
containing pyridine, shielded from light, as recently described by us
[30]. The crude product was isolated on a Discovery DSC-18 solid
phase extraction cartridge (Supelco, Gillingham, UK). The desired
compound was eluted with (5% MeCN-0.1% aq TFA) mobile phase:
and lyophilised. 2 was subsequently characterised by high resolution
mass spectrometry, and its purity conﬁrmed as N95% by analytical
RP-HPLC. The molecular weight of the conjugate is 3869 Da.
Fig. 1. Structures of modiﬁed tetraphenylporphyrin 1 and Tat-tetraphenylporphyrin
(Tat-TPP) bioconjugate 2.
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The experiments in this study were carried out using HN5 human
squamous cell carcinoma cells. HN5 cells were obtained from Prof.
Michael O'Hare (UCL Dept. of Surgery and Ludwig Institute for Cancer
Research, London, UK). Cells were cultured in Dulbecco's Modiﬁed
Eagle's medium containing 10% FBS (Sigma-Aldrich, Gillingham,
UK), 100 μM nonessential amino acid, 2 mM glutamine (Gibco BRL,
Life Technologies Ltd, Paisley, UK) and 500 μg/ml Gentamicin (Gibco
BRL, Life Technologies Ltd, Paisley, UK). Cells were incubated at
37 °C in a humidiﬁed atmosphere containing 5% CO2.
2.4. Preparation of Tat-TPP conjugate solutions in liposomes
In order to demonstrate that the Tat-TPP conjugate is capable of
partitioning to lipid membranes, spectroscopic studies were carried
out by mixing an aqueous solution of the conjugate with an aqueous
dispersion of liposomes. Stock solutions of the Tat-TPP conjugate
were prepared by dissolving the powder in water at a concentration
of 100 μM. The aqueous dispersions of DMPC (dimyristoyl phosphati-
dylcholine, Sigma-Aldrich, Gillingham, UK) liposomes were prepared
according to the procedure described by Hope et al. [39]. A ﬁlm of
lipid (total 20 μmol) was prepared on the inside wall of a round bot-
tom ﬂask by evaporation of CHCl3 solutions containing the required
amount of DMPC to obtain the molar percentage mixture. The
obtained ﬁlms were stored in a desiccator overnight under partial
evacuation and were then admixed with 1 ml of PBS buffer solution
in order to obtain lipid dispersions (12.5 mM). The solutions were
vortex-mixed and then freeze-thawed six times from liquid nitrogen
to 313 K (40 °C). Dispersions were then extruded (10 times)
through a 100 nm polycarbonate membrane (Whatman Nuclepore,
Maidstone, UK). The extrusions were carried out at 307 K (34 °C),
well above the transition temperature of DMPC (297.2 K), using a
2.5 ml extruder (Lipex Biomembranes Inc., Vancouver, Canada).
2.4.1. Photophysical characterisation
Absorption spectra were measured using a Perkin-Elmer Lambda
25 UV/Vis spectrometer (Perkin-Elmer, Beaconsﬁeld, UK) with quartz
cuvettes. Spectra were measured with samples prepared from the
stock solution using different solvents, e.g. water, methanol, or deu-
terated methanol (CH3OD) (Sigma-Aldrich, Gillingham, UK). Theﬂuorescence emission and excitation spectra of the conjugate in
aqueous and liposomal solutions were measured using a LS50B
Perkin-Elmer spectroﬂuorimeter (Perkin-Elmer, Beaconsﬁeld, UK). A
front surface excitation/detection geometric conﬁguration was used
to minimise self-absorption artefacts.
2.4.2. Fluorescence lifetime measurements
Fluorescence lifetimes were measured using the time-correlated sin-
gle photon counting method (TCSPC). Dilute solutions in methanol at a
concentration of 0.5 μMwere employed. The light source was a 405 nm
pulsed laser diode (EPL-405, Edinburgh Instruments Ltd., Livingston,
UK) with a pulse duration of 90 ps, and 5 MHz repetition rate. The ﬂuo-
rescence was detected using a fast multialkali photomultiplier module
(model H5773-04, Hamamatsu Photonics UK Ltd, Hertfordshire, UK)
via a longpass ﬁlter (OG510, Schott, Stafford, UK) and a monochromator
(model M300, Bentham Instrument Ltd, Berkshire, UK). TCSPC was car-
ried out using a PC-mounted board (TimeHarp100, PicoQuant GmbH,
Berlin, Germany) and lifetimes were derived using FluoFit software
(PicoQuant GmbH, Berlin, Germany). The Instrument Response Function
(IRF) was obtained from a non-ﬂuorescent scattering Ludox® solution
(Sigma-Aldrich, Gillingham, UK). Optimum ﬁtting with minimisation of
the residuals was conﬁrmed using a Chi-squared value χ2b1.4.
2.4.3. Singlet oxygen yield measurements
The singlet oxygen phosphorescence at 1270 nm was detected using
time-resolved photon counting from aerated solutions in deuterated
methanol (CH3OD) in quartz cuvettes. For detection in thenear-IR, a ther-
moelectrically cooled photomultiplier (model H10330-45, Hamamatsu
Photonics Ltd, Hertfordshire, UK) was used, and emission was collected
via a series of lenses from the cuvette in combination with a long-pass
and a band-pass ﬁlter centred at 1270 nm (Infrared Engineering Ltd,
Essex, UK). The solutionswere excited using a 532 Nd:YAG laser (Luma-
nova GmbH, Hannover, Germany) with the beam axis aligned orthogo-
nally to the collection optics. The laser was pulsed at a repetition rate of
3 kHz and a pulse length of 3 ns, giving a mean power of 8 mW, and a
fast photodiode (1 ns rise time, Becker-Hickl, Berlin, Germany) was
used to synchronise the laser pulse with the photon counting detection
system. A series of neutral density ﬁlters was used to attenuate the laser
power. The photon counting equipment consisted of a PC-mounted
multiscaler board (model MSA-300, Becker-Hickl, Berlin, Germany)
and a pre-ampliﬁer (Becker-Hickl, Berlin, Germany) which gave a reso-
lution of 5 ns per channel. Time-resolved phosphorescence measure-
ments were accumulated by the multiscaler board. The traces were
analysed using FluoFit software (PicoQuant GmbH, Berlin, Germany) to
extract the singlet oxygen decay lifetime. To calculate the quantum
yield the standard zero-time intercept analysiswas used. TPPS4 (tetrasul-
fonated tetraphenylporphine) was chosen as the reference compound
[40,41].
2.5. Cellular uptake of Tat-TPP
HN5 cells were seeded in 96-well plates at 2.5×104 cells/well one
day before drug application. For the time-dependent cell uptake exper-
iment, cells were treated with 1 μM Tat-TPP added from an aqueous
stock solution for various time periods up to 8 h. For temperature-
dependent experiments, all protocolswere the same except that the in-
cubations of photosensitisers were performed at 4 °C or 37 °C for 1 h.
For the dose-dependent uptake measurement, cells were incubated
with Tat-TPP with different concentrations from 0.1 μM to 5 μM for
18 h. Comparative studies were carried out following the same proto-
cols with 1 μg/ml (1.3 μM) TPPS2a instead. At the selected uptake mea-
surement time points, cells were washed with PBS and incubated in
clear DMEMmedium (no phenol red; no serum) for ﬂuorescence mea-
surement using a spectroﬂuorimeter with a ﬁbre-optic attachment
designed to record ﬂuorescence from 96 well plates (LS50B spectroﬂu-
orimeter, Perkin-Elmer, Beaconsﬁeld, UK).
Fig. 2. Absorption spectrum of 5 μM Tat-TPP conjugate in aqueous solution. Inset: the Q
band region from 450 nm to 700 nm.
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studies using confocal microscopy
HN5 cells were seeded overnight in Petri dishes incorporating a cov-
erslipwindowon the underside designed formicroscopy (FluoroDish™,
World Precision Instruments, Stevenage, UK) and were then incubated
with 2.5 μM Tat-TPP for 18 h. After being thoroughly washed and incu-
bated with fresh full medium for further 4 h, cells were incubated with
clear phenol red-free DMEM for ﬂuorescence microscopy. The cellular
distribution and redistribution after 10 min light irradiation were ob-
served by confocal microscopy (FluoView FV1000, 60× magniﬁcation,
NA 1.20, Olympus UK Ltd, Essex, UK). The light treatment was carried
out on stage by using the 543 nm laser of the microscope. Fluorescence
images were taken during the irradiation process at several time
points. For co-localisation studies, after the 18 h incubation with the
Tat-TPP conjugate (2.5 μM), and thrice washing and a further 4 h incu-
bation with fresh medium, cells were incubated for 30 min with
50 nM LysoTracker Green for lysosomal labelling or MitoTracker Green
(Molecular Probes, Paisley, UK) formitochondrial labelling. Clearmedium
was again used for live cell imaging using confocal microscopy.
2.7. Phototoxicity of Tat-TPP and its PCI effect in combination with
saporin
HN5 cells were seeded at 5000 cells/well in 96-well plates over-
night. Cells were treated with the Tat-TPP conjugate (0.05, 0.1 and
0.2 μM) or saporin (Sigma-Aldrich Gillingham, UK) (10, 25 nM) for
18 h separately. Another three groups of cells were co-incubated
with saporin (10, 25 or 50 nM) and 0.1 μM Tat-TPP. Cells were thenFig. 3. Fluorescence spectrum of 2.5 μM Tat-TPP in aqueous and DMPC liposomal solu-
tions. A: Emission spectra (λexcitation 420 nm); B: excitation spectra (λemission 651 nm).
The emission spectra were corrected for the variation of detector sensitivity with
wavelength. Front surface excitation/detection geometry was employed to minimise
self-absorption.washed thrice with PBS and incubated a further 4 h with fresh full
medium. Irradiation was carried out for up to 5 min using a blue
LumiSource® ﬂatbed lamp with peak emission c. 420 nm and
7 mW cm−2 output (PCI Biotech, Oslo, Norway). Cell viability was de-
termined by means of the standard MTT (3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide) (Sigma-Aldrich, Gillingham,
UK) assay 2 days after the light exposure.
2.8. Statistical analysis
Results are presented as mean±standard deviation (SD). Signiﬁcant
differences were assessed by two-tailed Student's t-test analysis.
p≤0.05 was considered statistically signiﬁcant.
3. Results
3.1. Spectroscopic studies
The structure of the peptide-porphyrin conjugate is shown in
Fig. 1. The lipophilic tetraphenyl porphyrin is coupled via a linker to
the Tat peptide, which is cationically charged since the peptide con-
tains several amino groups which will be protonated at physiological
pH. The peptide comprises the core HIV-1 Tat 48–57 sequence, with a
C-terminal tetrapeptide extension containing cysteine, as described
by Santra et al. [38], to allow attachment of a functionalised porphyrin
by bioorthogonal thiol-maleimide ligation (see Section 2.2).
With this amphiphilic structure, the bioconjugate should in principle
localise well in membranes with the hydrophobic porphyrin localised
within the lipid membrane and the cationic Tat sequence residing at
the anionic membrane surface. Based on this reasoning it was hypothe-
sised that this bioconjugate would be effective for PCI.
3.2. Spectroscopic analysis of Tat-TPP
Fig. 2 shows the absorbance spectrum of 5 μM Tat-TPP conjugate
in aqueous solution (distilled water). The peak absorption of the
Soret band was observed at 418 nm. The weaker series of Q band ab-
sorption peaks are shown in the inset with the longest wavelength
peak in red at 642 nm (Fig. 2, inset). In methanol, the peak absorption
was observed at 414 nm. At this wavelength, the molar extinction co-
efﬁcient was measured as 2.9×105 M−1 cm−1 in methanol.
The ﬂuorescence emission and excitation spectra of the Tat-TPP
conjugate in aqueous and DMPC liposomal solutions are shown in
Fig. 3. Peak ﬂuorescence emission in aqueous solution was detected
at 652 nm and 714 nm, and the maximum excitation intensity was
at 417 nm (λemission 651 nm). Red-shifted ﬂuorescence spectra were
observed in the liposomal solution with peak ﬂuorescence emission
detected at 655 nm and 721 nmwhile the maximum excitation inten-
sity was recorded at 420 nm.
3.3. Photophysical studies
In order to minimise dimerisation due to the hydrophobic TPP
moiety in the conjugate, methanol was chosen as the solvent for
the ﬂuorescence lifetime measurement. For the determination of the
singlet oxygen quantum yield, deuterated methanol (CH3OD) was
used. To conﬁrm that the methanolic solutions at the concentrations
studied were monomeric, absorption spectra were recorded as a
function of concentration. It was necessary to check for the presence
of any aggregation because aggregated porphyrins exhibit shorter
ﬂuorescence lifetimes and lower singlet oxygen quantum yields.
The absorption spectra of the Tat-TPP conjugate were measured in
methanol and deuterated methanol and the peak absorbance of the
Soret Band (at 414 nm) was found to be linear versus concentration up
to 2 μM conﬁrming that Tat-TPP conjugate was present in monomeric
form.
Fig. 4. Cellular ﬂuorescence levels of Tat-TPP in comparison with TPPS2a in HN5 cells.
A: Cells were incubatedwith Tat-TPP (1 μM) and TPPS (1.3 μM) for 8 h. B: Cells were
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Themeasurement of theﬂuorescence lifetime of Tat-TPP inmethanol
(0.5 μM) exhibited a good mono-exponential decay ﬁtting with the
value of 8.7 ns (Table 1). A slightly longer value was observed in deuter-
ated methanol (10.7 ns) as expected due to the isotope effect. For com-
parison, the lifetime of TPPS4 was measured as 9.7 ns in methanol.
3.3.2. Singlet oxygen quantum yield
The quantum yield of the Tat-TPP conjugate was measured in
comparison with that of a known reference compound, TPPS4
(ΦΔ=0.7 in CH3OD) [40,41]. Using standard zero-point intercept
analysis with optically matched solutions [42], the singlet oxygen
quantum yield of Tat-TPP was calculated as 0.54.
3.4. Cellular uptake of Tat-TPP in comparison with TPPS2a
Human squamous cell carcinoma HN5 cells were incubated with
the Tat-TPP conjugate or the amphiphilic sulfonated derivative,
TPPS2a and cellular ﬂuorescence levels were compared as a function
of time or concentration. Control cells without applied drug exhibited
negligible ﬂuorescence levels. As shown in Fig. 4A, time-dependent
cell uptake was found for both photosensitisers. Higher ﬂuorescence
levels were measured in cells treated with Tat-TPP (1 μM) compared
to TPPS2a (1.3 μM) at longer incubation times even though the con-
centration of Tat-TPP was slightly lower. The variation in cellular ﬂuo-
rescence versus concentration up to 5 μM recorded at 18 h, the time-
point used in subsequent PCI studies, shown in Fig. 4B. Above 1 μM,
relatively little increase in ﬂuorescence levels was observed. In addi-
tion, after 18 h incubation, the ﬂuorescence intensity was measured
to be three times higher in cells treated with 0.1 μM Tat-TPP, the con-
centration used in subsequent PCI studies, compared with TPPS2a
using the same concentration.
To study the uptake mechanism of Tat-TPP and the possible in-
volvement of endocytosis, which is temperature-dependent unlike
passive transport, experiments using low temperature incubation
were performed. The cellular uptake of Tat-TPP exhibits a tempera-
ture dependence, as shown in Fig. 4C. Incubation at 4 °C resulted in
a signiﬁcant reduction of cellular uptake compared to incubation at
37 °C (pb0.01). The same behaviour was also observed in the cells in-
cubated with TPPS2a, which is known to be taken up via endocytosis
[37].
3.5. Subcellular localisation and light-induced redistribution of Tat-TPP
using confocal microscopy
After 18 h incubation, a granular intracellular distribution of the
Tat-TPP conjugate was observed by confocal microscopy (Fig. 5A),
which became diffuse following prolonged light exposure (Fig. 5B).Table 1
A summary of the photophysical properties of the Tat-TPP conjugate. λabs Soret: the peak
Soret band absorption; λabs Q: the peak Q band absorption in the red spectral region;
λex: the ﬂuorescence excitation wavelengthmaxima (λemission 651 nm); λem: the ﬂuores-
cence emission wavelength maxima (λexcitation 420 nm); τF: ﬂuorescence lifetime; ΦΔ:
singlet oxygen quantum yield.
dH2Oa MeOHb DMPCc MeODd
λabs Soret (nm) 418 414 – –
λabs Q (nm) 642 645 – –
λex (nm) 417 – 420 –
λem (nm) 652, 714 – 655, 721 –
τF (ns) – 8.7 – 10.7
ΦΔ – – – 0.54
a Distilled water.
b Methanol.
c DMPC liposomal solution.
d Deuterated methanol.
2a
incubated with Tat-TPP (up to 5 μM) for 18 h. C: Normalised cellular ﬂuorescence
levels of Tat-TPP (1 μM) and TPPS2a (1.3 μM) at 4 °C or 37 °C after 1 h incubation.The exposure time needed to acquire the images was small (b10 s)
compared with the duration of the light exposure required to induce
the redistribution (10 min). A slight increase of about 20% in integrat-
ed cellular ﬂuorescence intensity accompanied the redistribution
which we have also observed in similar experiments using aluminium
disulfonated phthalocyanine and is believed to result from the reduc-
tion in concentration self-quenching of ﬂuorescence [43].
The subcellular localisation of Tat-TPP (Fig. 6A and D) was investi-
gated by co-labelling cells with LysoTracker Green (Fig. 6B) or Mito-
Tracker Green (Fig. 6E), since a granular or punctate subcellular
distribution can be associated with either lysosomal or mitochondrial
uptake. As shown in the merged images Fig. 6C and F, most Tat-TPP
was found co-localised with lysosomes (yellow). Less overlap was ap-
parent using the mitochondrial probe.
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cells
The phototoxicity of the Tat-TPP conjugate in HN5 cells was studied
as a function of both incubation concentration (up to 0.2 μM) and differ-
ent light exposures (Fig. 7, black, dark and light blue lines). The photo-
toxicity induced by Tat-TPP was found to increase with both the light
and drug dose. Cell viability was reduced to 40% and 25% using the con-
jugate at concentrations of 0.1 μM and 0.2 μM respectively after 3 min
light exposure, which corresponds to a ﬂuence of 1.3 J cm−2 Control
values without light exposure are given by the ordinate readings,
which show that little dark toxicity was evident induced by the conju-
gate. Controls performedwith light only showed nomeasureable reduc-
tion in viability.
Previous studies have shown that a sub-lethal combination of
photosensitiser and light dose, corresponding to c. 50% reduction in
viability, is the optimal condition for PCI treatment [35,37]. The PCI
effect in combination with saporin was therefore examined using a
concentration of 0.1 μM and 3 min light exposure for the Tat-TPP con-
jugate. In Fig. 7, the solid purple and orange lines represent the cell vi-
ability after being treated with increasing doses of saporin alone (10
and 25 nM). Control values for saporin only without light exposure
are given by the ordinate readings. After light exposure there was
no signiﬁcant enhancement in toxicity with saporin only, and the vi-
ability at the 3 min time point was measured as 56% for 10 nM
saporin. However, signiﬁcantly enhanced cell killing (pb0.001) was
demonstrated by PCI using Tat-TPP in combination with saporin atFig. 5. Cellular distribution of Tat-TPP and the redistribution after irradiation on stage
in HN5 cells by confocal microscopy. A: Before light; B: 10 min light exposure. Light
source: 543 nm confocal microscope laser. Cells were incubated with 2.5 μM Tat-TPP
for 18 h. Scale bar: 20 μm.each dose (dotted lines), and for 10 nM the viability was reduced to
5%. In summary, using 10 nMsaporin and 0.1 μMTat-TPP, PCI treatment
signiﬁcantly reduced the cell viability by factors of 11.2 and 7.3 com-
pared to saporin and Tat-TPP alone respectively after 3 min light expo-
sure. PCI using the Tat-TPP conjugate therefore signiﬁcantly enhanced
the cytotoxicity induced by the type I RIP toxin, saporin.
4. Discussion
In this study a cell penetrating peptide containing the core Tat se-
quence conjugated to a porphyrin (TPP) photosensitiser was investi-
gated for photochemical internalisation (PCI), which is a site-speciﬁc
technique for improving drug delivery. The key property required of a
photosensitiser designed for PCI is the ability to localise speciﬁcally in
endo/lysosomal membranes. This is a key difference from photosensi-
tisers designed for photodynamic therapy (PDT) where localisation in
other subcellular compartments may confer an advantage (e.g. in mi-
tochondria) rather than the speciﬁc endo/lysosomal localisation re-
quired for PCI. The efﬁcacy of the water soluble peptide-porphyrin
bioconjugate for PCI was investigated in a human head and neck
squamous cell carcinoma cell line, which was selected on the basis
that PCI may be suited to head and neck cancer therapy. PCI is cur-
rently undergoing a Phase 1 clinical trial at University College Hospi-
tal in London, including treatment of head and neck tumours. Prior to
the cellular studies, a series of spectroscopic and photophysical stud-
ies of the conjugate were carried out in different solvents, including a
liposomal solution, to investigate its physicochemical properties. The
Tat-TPP conjugate displayed typical ﬂuorescence spectra in aqueous
solution for a tetraphenyl porphyrin with two emission bands, but a
red shift was observed in aqueous solution containing DMPC lipo-
somes in both excitation and emission spectra (Fig. 3), which would
be consistent with binding of the conjugate to the liposomal mem-
brane. Such spectral shifts upon membrane binding of porphyrins
have been reported in numerous studies [44,45]. This result would
imply that the bioconjugate should also bind to cellular/organelle
membranes, which is a key property required of photosensitisers
used for PCI [46]. In support of this general conclusion, we have also
demonstrated photoinduced membrane permeation by the same
Tat-porphyrin conjugate in relation to their antibacterial PDT effects
[30] as discussed below, where a different phospholipid composition
was employed. The ﬂuorescence lifetime of Tat-TPP in methanol was
measured as 8.7 ns compared to a value of 9.7 ns for TPPS4 which is in
good agreement with the result from another study [47]. The singlet
oxygen yield of the Tat-TPP conjugate was determined in methanol,
giving ΦΔ=0.54, which is close to a reported value of 0.56 for TPP
[46].
The cellular uptake of the Tat-TPP conjugate was investigated in
the HN5 human squamous cell carcinoma line in comparison to
TPPS2a which is an amphiphilic tetraphenyl porphyrin used for both
PCI and PDT. The results in Fig. 4A show that the conjugate was
taken up by cells efﬁciently with ﬂuorescence levels comparable to
those using a similar concentration of TPPS2a. Incubation at 4 °C re-
duced the uptake of both photosensitisers, although to a lesser extent
with the conjugate, which is consistent with the involvement of an
energy-dependent endocytic mechanism of cellular uptake (Fig. 4C).
The residual uptake of the conjugate may be due to binding of the cat-
ionic Tat peptide to the cell membrane as previously reviewed [48].
The subcellular distribution of the Tat-TPP conjugate was observed
to be similar to TPPS2a (data not shown) exhibiting a granular pattern
which became diffuse after light exposure (Fig. 5), which is consistent
with the endo/lysosomal rupture mechanism required for PCI. Co-
localisation studies with lysosomal and mitochondria probes showed
that the conjugate appears to accumulate mainly in lysosomes as a
consequence of endocytic cellular uptake. Since the molecular weight
of the Tat conjugate is approx. 4000 Da, endocytic uptake would be
expected for a molecule of this size. Overall, the results indicate that
Fig. 6. Colocalisation studies of Tat-TPP versus LysoTracker Green or MitoTracker Green
in HN5 cells by confocal microscopy. Cells were incubated 2.5 μM Tat-TPP for 18 h.
50 nM of LysoTracker Green or MitoTracker Green was applied to cells 30 min before
imaging. A and D: Tat-TPP; B: LysoTracker Green; C: merged A and B; E: MitoTracker
Green; F: merged D and E. Scale bar: 20 μm.
Fig. 7. Tat-TPP PDT (without saporin) and PCI effect (with saporin) in HN5 cells. Cells
were incubated with 0.1 μM or 0.2 μM Tat-TPP, with or without saporin (10, 25 nM)
for 18 h. Irradiationwas carried out up to 5 min using a blue lamp. Cell viability was exam-
ined by the MTT assay 48 h after exposure to light.
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gates, and that the conjugate is likely to be bound to the endo/
lysosomal membrane instead of the aqueous lysosomal compartment
based on the observation of membrane binding in the liposome
studies. In a previous study, we investigated the photoinduced
membrane permeation by the same Tat-porphyrin conjugate in rela-
tion to their antibacterial PDT effects [30]. Photo-induced release of
carboxyﬂuorescein entrapped within unilamellar vesicles prepared
from negatively charged lipids was observed, which mirrors the
light-induced intracellular redistribution observed in the present
study. Collectively, the experimental results presented here are in
agreement with results of Vicente and co-workers that Tat-
porphyrin conjugates are taken up efﬁciently by cells and can display
an endo/lysosomal intracellular localisation [29,49,50]. Moreover, in
another study it was found cationic porphyrins without the peptide
component exhibited preferential mitochondrial uptake, which ren-
ders them unsuitable for PCI [50]. The serum stability of peptide-
porphyrin conjugates [49] has also been investigated and it was
found that these conjugates can undergo partially hydrolysis by pro-
teolytic enzymes after 24 h incubation. It is possible that the conju-
gate used here may undergo similar processes, although this should
have no effect upon the efﬁciency of subsequent photoinduced mem-
brane damage, and further studies need to be carried out on theoptimum incubation time. The choice of the 18 h incubation time
used here was based on previous PCI studies with other porphyrin
photosensitisers.
To test whether the Tat-TPP conjugate has the potential for PCI, its
phototoxicity was examined in the HN5 line in combination with the
macromolecular toxin, saporin. As shown in Fig. 7, Tat-TPP induced
phototoxicity using low concentrations, and a sub-lethal combination
of photosensitiser and light dose suitable for PCI was identiﬁed. The
signiﬁcantly enhanced cell killing achieved by combining low concen-
trations of saporin with a sub-lethal light dose demonstrated that the
Tat-TPP conjugate is capable of acting as a PCI photosensitiser, since
the same concentrations of saporin used without illumination are
non-toxic. The PCI effect using Tat-TPP was found to be comparable
to another PCI photosensitiser TPPS2a in which the combination of
sub-lethal PDT and saporin treatment induced 95% reduction of cell
viability [35,36]. The concentration employed here for the Tat-TPP
conjugate of 0.1 μM is comparable to concentrations employed for
PCI with TPPS2a. However since we observed higher cellular ﬂuores-
cence levels using the conjugate than TPPS2a (Section 3.4), future
studies may therefore be able to employ even lower concentrations
of the conjugate, and also demonstrate PCI with lower saporin con-
centrations. It is possible that the presence of the Tat-TPP conjugate
itself could have modiﬁed endosomal release and thus toxicity of
the saporin in the absence of light, but inspection of the data points
on the ordinate of Fig. 7 corresponding to zero illumination shows
no evidence for any synergistic interactions.
The present study is the ﬁrst attempt to incorporate the cell pene-
trating peptide-photosensitiser conjugation strategy for PCI-enhanced
delivery of a macromolecular toxin. The growing number of cell pene-
trating peptides that are becoming available [4,51] together with efforts
to incorporate tumour targeting, add to the versatility of this approach.
In summary, it has been demonstrated that a CPP-photosensitiser con-
jugate exhibits favourable properties for PCI. Firstly, the combination
of good photophysical properties, water solubility yet sufﬁcient amphi-
philicity to localise in membranes. Secondly, efﬁcient cellular uptake
and lowdark toxicity, andﬁnally the synergistic PCI cytotoxicity in com-
bination with saporin. A further advantage is that conjugation to a CPP
enables not only photosensitisers like TPPs to be used, but other photo-
sensitisers with extended and stronger red absorption than porphyrins,
which on their ownwould not be suitable for PCI applications since they
lack the required amphiphilic properties. Not surprisingly, some studies
have pointed out that Tat peptide bioconjugates may perform different-
ly in vitro and in vivo [52,53], therefore future in vivo studies need to
carefully consider the differences in experimental settings. Although
limited cell speciﬁcity has been a drawback in the use of CPPs such as
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of CPPs increases.Moreover, PCI selectivity can also be achieved through
its light-activated site speciﬁcity so that the therapeutic effects are con-
ﬁned to the area exposed to light.
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